Inventor · disambiguated record
Louis G. Lange, Iii
Also filed as: LANGE III LOUIS G · LANGE LOUIS · LANGE LOUIS G · LANGE LOUIS GEORGE III
20 granted patents·5 pending applications·233 citations·filing 1977–2021
95Inventor score
Files withLANGE III LOUIS G4CV THERAPEUTICS3CV THERAPEUTICS INC3AMYGDALA NEUROSCIENCES INC2HARVARD COLLEGE2
Top patents by PatentIndex Score
25 records- 0179US5063210AUse of sulfated polysaccharides to decrease cholesterol and fatty acid absorptionLANGE III LOUIS G·Filed 1989·Granted Nov 5, 1991·54 cites·4 claims
- 0271US7071174B1Method and composition for inhibiting cholesterol esteraseCV THERAPEUTICS INC·Filed 2000·Granted Jul 4, 2006·2 cites·6 claims
- 0369US5432058AMethod for measuring human cholesterol absorption using metabolically stable isotopesFiled 1992·Granted Jul 11, 1995·35 cites·14 claims
- 0465US5484777APancreatic cholesterol esterase inhibitorFiled 1993·Granted Jan 16, 1996·22 cites·1 claims
- 0562US5017565AUse of sulfated polysaccharides to inhibit pancreatic cholesterol esteraseLANGE III LOUIS G·Filed 1989·Granted May 21, 1991·25 cites·2 claims
- 0662US4111751AMethod of purifying alcohol dehydrogenaseHARVARD COLLEGE·Filed 1977·Granted Sep 5, 1978·4 cites·11 claims
- 0760US5173408AMammalian pancreatic cholesterol esteraseLANGE LOUIS GEORGE III·Filed 1989·Granted Dec 22, 1992·21 cites·3 claims
- 0859US2009111826A1Use of ranolazine for the treatment of cardiovascular diseasesLANGE LOUIS·Filed 2008·Application pending·0 cites
- 0957US2010035890A1Use of ranolazine for the treatment of cardiovascular diseasesGILEAD PALO ALTO INC·Filed 2009·Application pending·0 cites
- 1056US5616570AUse of non-absorbable synthetic sulfated polysaccharides to decrease cholesterol absorbtionFiled 1994·Granted Apr 1, 1997·19 cites·12 claims
- 1156US4131727AMethod of purifying alcohol dehydrogenase and affinity resin thereforHARVARD COLLEGE·Filed 1978·Granted Dec 26, 1978·8 cites·3 claims
- 1254US5869537AMacrophage lipid chemoattractantCV THERAPEUTICS·Filed 1997·Granted Feb 9, 1999·10 cites·4 claims
- 1350US2021220376A1Addiction treatment of an alcohol-consuming patient populationAMYGDALA NEUROSCIENCES INC·Filed 2021·Application pending·0 cites
- 1449US5352601AMethod for recovering purified 52,000 dalton fraction of human pancreatic cholesterol esterase using deae-cellulose, hydroxyapatite and heparin-sepharoseLANGE III LOUIS G·Filed 1992·Granted Oct 4, 1994·9 cites·2 claims
- 1548US2020237789A1Combination therapy for preventing addictionAMYGDALA NEUROSCIENCES INC·Filed 2020·Application pending·0 cites
- 1648US2009312340A1Use of ranolazine for the treatment of cardiovascular diseasesWANG WHEDY·Filed 2009·Application pending·0 cites
- 1743US5624836ADNA encoding bovine pancreatic cholesterol esteraseFiled 1995·Granted Apr 29, 1997·6 cites·6 claims
- 1843US5492822AMethod for recovering purified 100,000 dalton molecular weight fraction of human pancreatic cholesterol esteraseLANGE III LOUIS G·Filed 1995·Granted Feb 20, 1996·4 cites·5 claims
- 1942US5521303AMethod of manufacturing non-absorbable synthetic sulfated polysaccharidesCV THERAPEUTICS INC·Filed 1994·Granted May 28, 1996·4 cites·11 claims
- 2034US5663450AMacrophage lipid chemoattractantCV THERAPEUTICS·Filed 1995·Granted Sep 2, 1997·1 cites·5 claims
- 2133US6632801B1Method and composition for inhibiting human cholesterol esteraseCV THERAPEUTICS INC·Filed 1997·Granted Oct 14, 2003·1 cites·16 claims
- 2233US5679375AMethod of treating ulcers with sulfated polysaccharidesC V THERAPEUCTICS·Filed 1995·Granted Oct 21, 1997·4 cites·3 claims
- 2330US5429937AMethod for recovering purified 100,000 molecular weight fraction of human pancreatic cholesterol esterase using heparin agaroseCV THERAPEUTICS·Filed 1994·Granted Jul 4, 1995·2 cites·1 claims
- 2429US5792832APeptides from mammalian pancreatic cholesterol esteraseFiled 1995·Granted Aug 11, 1998·0 cites·2 claims
- 2523US6107026AMethods and reagents for RFLP analysis of the human pancreatic cholesterol esterase geneFiled 1995·Granted Aug 22, 2000·2 cites·11 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →